Your Partner for Growth, Hybridan

Hybridan

Your Partner for Growth

Our passion is raising growth capital for exciting, fast growth companies that want to take their business to the next level. We raise capital for companies both listed and unlisted in the most efficient manner possible and pride ourselves as being one of the few consistently profitable broking firms in the City. This has been achieved through a highly disciplined approach when seeking to create both corporate and institutional relationships.

Equity Bottom-Up

<ul>
<li>The provider of data and technology for sports, fitness and wellness organisations to optimise operational and investment decisions, announced that, following a competitive tender, it has secured a contract renewal and expansion with Sport England worth up to £4m over four years in equal terms.</li>
<li>Sport England initially procured 4GLOBAL in 2021 to provide performance data from public leisure facilities through its platform, Moving Communities, a decision-support tool that uses 4GLOBAL's dataset to aid understanding of where and how people engage in physical activity, enabling a more evidence-based approach to public investment.</li>
<li>The platform has since played a central role in programmes such as the National Leisure Recovery Fund and the Swimming Pool Support Fund, tracking over 9 million active people across 1,000+ leisure facilities daily.</li>
</ul>


The provider of data and technology for sports, fitness and wellness organisations to optimise operational and investment decisions, announced that, following a competitive tender, it has secured a contract renewal and expansion with Sport England worth up to £4m over four years in equal terms.
Sport England initially procured 4GLOBAL in 2021 to provide performance data from public leisure facilities through its platform, Moving Communities, a decision-support tool that uses 4GLOBAL's dataset to aid understanding of where and how people engage in physical activity, enabling a more evidence-based approach to public investment.
The platform has since played a central role in programmes such as the National Leisure Recovery Fund and the Swimming Pool Support Fund, tracking over 9 million active people across 1,000+ leisure facilities daily.


Research from Hardman & Co, Hardman & Co

Hardman & Co

Research from Hardman & Co

Investment research on quoted companies and funds

Hardman & Co is a multi-disciplinary financial consultancy and investment research firm, employing highly experienced analysts and professionals with a broad range of capital markets expertise. Our clients are public and private businesses as well as fund managers, ranging from start-ups to £1 billion+ market capitalisations. Hardman & Co offers corporate research & consultancy, serving the needs of both public and private companies. We produce gold-standard research with a global reach for trading and investment companies, as well as providing market commentary and analysis. In addition, we carry out a number of bespoke investment-related assignments, including due diligence on bond listings, assessments of private company valuations and other corporate advisory services. We engage with the market through traditional and digital media, offering illuminating video content on corporate management strategy, results communication, interviews and in-house sector discussion.

Thematic (Sector/Industry)

<ul>
<li>The Hardman &amp; Co Healthcare Index (HHI) has been running since 2009.</li>
<li>Its main function is to highlight the attractions of life sciences investments over the long term.</li>
<li>For the third year running, despite generally good returns in global markets, particularly in the US, performance in 2024 was poor, not helped by the capital-intensive nature of the sector.</li>
</ul>


The Hardman &amp; Co Healthcare Index (HHI) has been running since 2009.
Its main function is to highlight the attractions of life sciences investments over the long term.
For the third year running, despite generally good returns in global markets, particularly in the US, performance in 2024 was poor, not helped by the capital-intensive nature of the sector.


Hardman & Co Healthcare Index: 2024 – Tough year for Life Sciences

Finland

Faron Pharmaceuticals Oy operates as a drug discovery and development company in Finland. It has a pipeline of clinical stage products focusing on acute organ traumas, cancer immunotherapy, and vascular damage. The company?s lead product candidate includes Traumakine, a recombinant human IFN beta-1a, which is Phase III clinical trial for the treatment of acute respiratory distress syndrome (ARDS). It is also developing Clevegen, a pre-clinical immunotherapy candidate, designed to prevent tumor growth and metastasis which targets the tumor immune suppressor molecule; Farbetic, an AOC3 inhibitor, for use in the prevention of vascular deformations in various disease conditions, such as diabetes; and D-ARDS, a diagnostic tool to estimate ARDS severity and to follow ARDS outcome. The company was founded in 2003 and is based in Turku, Finland. Faron Pharmaceuticals Oy is a subsidiary of Faron Ventures Oy.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Faron Pharmaceuticals Oy (FARN LN)

Hybridan Small Cap Feast: 03/04/2025

Sport England initially procured 4GLOBAL in 2021 to provide performance data from public leisure facilities through its platform, Moving Communities

Hybridan

Hardman & Co Healthcare Index: 2024 – Tough year for Life Sciences

The Hardman & Co Healthcare Index (HHI) has been running since 2009. Its main function is to highlight the attractions of life sciences investments...

Hardman & Co

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)